Cowpea Mosaic Virus Immunotherapy Combined with Cyclophosphamide Reduces Breast Cancer Tumor Burden and Inhibits Lung Metastasis. Issue 16 (19th June 2019)

• Record Type: Journal Article
• Authors: Cai, Hui; Wang, Chao; Shukla, Sourabh; Steinmetz, Nicole F.
• Is Part Of: Advanced science. Volume 6:Issue 16(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-06-19
• Subjects: cancer immunotherapy -- chemotherapy -- in situ vaccination -- triple‐negative breast cancer; Science -- Periodicals; 505
• DOI: 10.1002/advs.201802281
• Languages: English
• ISSNs: 2198-3844

Abstract

Abstract: Patients with metastatic triple‐negative breast cancer (TNBC) have a poor prognosis, so new therapies or drug combinations that achieve more effective and durable responses are urgently needed. Here, a combination therapy using cowpea mosaic virus (CPMV) and low doses of cyclophosphamide (CPA) is developed with remarkable synergistic efficacy against 4T1 mouse tumors in vivo. The combination therapy not only attenuates the growth of primary tumor and increases survival, but also suppresses distant tumor growth and reduces lung metastasis. Mechanistic analysis indicates that the combination of CPMV and CPA increases the secretion of several cytokines, activates antigen‐presenting cells, increases the abundance of tumor infiltrating T cells, and systematically reverses the immunosuppression. These results show that the combination of CPMV in situ vaccination with chemotherapy may become a potent new strategy for the treatment of TNBC. Abstract : A combination therapy is developed to treat metastatic triple‐negative breast cancer by combining cowpea mosaic virus in situ vaccination and chemo‐induced immunogenic cell death. The combination therapy induces systematic antitumor immunity with synergistic efficacy against both the treated and nontreated tumor, and can also reduce the lung metastasis.